{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:54:43Z","timestamp":1793490883057,"version":"4.5.0"},"reference-count":76,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T00:00:00Z","timestamp":1688860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione Ricerca Fibrosi Cistica Onlus","doi-asserted-by":"publisher","award":["FFC#5\/2022"],"award-info":[{"award-number":["FFC#5\/2022"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Reverse vaccinology is a powerful tool that was recently used to develop vaccines starting from a pathogen genome. Some bacterial infections have the necessity to be prevented then treated. For example, individuals with chronic pulmonary diseases, such as Cystic Fibrosis, are prone to develop infections and biofilms in the thick mucus that covers their lungs, mainly caused by Burkholderia cepacia complex, Haemophilus influenzae, Mycobacterium abscessus complex, Pseudomonas aeruginosa and Staphylococcus aureus. These infections are complicated to treat and prevention remains the best strategy. Despite the availability of vaccines against some strains of those pathogens, it is necessary to improve the immunization of people with Cystic Fibrosis against all of them. An effective approach is to develop a broad-spectrum vaccine to utilize proteins that are well conserved across different species. In this context, reverse vaccinology, a method based on computational analysis of the genome of various microorganisms, appears as one of the most promising tools for the identification of putative targets for broad-spectrum vaccine development. This review provides an overview of the vaccines that are under development by reverse vaccinology against the aforementioned pathogens, as well as the progress made so far.<\/jats:p>","DOI":"10.3390\/vaccines11071221","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:35:21Z","timestamp":1688949321000},"page":"1221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improving Protection to Prevent Bacterial Infections: Preliminary Applications of Reverse Vaccinology against the Main Cystic Fibrosis Pathogens"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7074-0328","authenticated-orcid":false,"given":"Mario","family":"Cocorullo","sequence":"first","affiliation":[{"name":"Department of Biology and Biotechnology \u201cLazzaro Spallanzani\u201d, University of Pavia, Via A. Ferrata 9, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-9764","authenticated-orcid":false,"given":"Laurent R.","family":"Chiarelli","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cLazzaro Spallanzani\u201d, University of Pavia, Via A. Ferrata 9, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5219-4770","authenticated-orcid":false,"given":"Giovanni","family":"Stelitano","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cLazzaro Spallanzani\u201d, University of Pavia, Via A. Ferrata 9, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clinimag.2022.02.004","article-title":"Cystic fibrosis in the 21st century: What every radiologist should know","volume":"84","author":"Hallouch","year":"2022","journal-title":"Clin. Imaging"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Recchia, D., Stelitano, G., Stamilla, A., Gutierrez, D.L., Degiacomi, G., Chiarelli, L.R., and Pasca, M.R. (2023). Mycobacterium abscessus infections in cystic fibrosis individuals: A review on therapeutic options. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054635"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e0041922","DOI":"10.1128\/spectrum.00419-22","article-title":"Bacterial culture underestimates lung pathogen detection and infection status in cystic fibrosis","volume":"10","author":"Gavillet","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fcimb.2020.00213","article-title":"Bacterial community interactions during chronic respiratory disease","volume":"10","author":"Welp","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41396-021-01130-6","article-title":"Inter-species interactions alter antibiotic efficacy in bacterial communities","volume":"16","author":"Bottery","year":"2022","journal-title":"ISME J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Manos, J. (2021). Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections. Microorganisms, 9.","DOI":"10.3390\/microorganisms9091874"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Scoffone, V.C., Trespidi, G., Chiarelli, L.R., Barbieri, G., and Buroni, S. (2019). Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081838"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.medmal.2015.11.013","article-title":"Vaccine strategies against bacterial pathogens in cystic fibrosis patients","volume":"46","author":"Gaillard","year":"2016","journal-title":"Med. Mal. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tahamtan, A., Charostad, J., Hoseini Shokouh, S.J., and Barati, M. (J. Arch. Mil. Med., 2017). An overview of history, evolution, and manufacturing of various generations of vaccines, J. Arch. Mil. Med., in press.","DOI":"10.5812\/jamm.12315"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cvsm.2017.10.002","article-title":"Recent Advances in vaccine technologies","volume":"48","author":"Francis","year":"2018","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nrmicro2893","article-title":"Structural vaccinology starts to deliver","volume":"10","author":"Dormitzer","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/vim.2017.0143","article-title":"Measles vaccine","volume":"31","author":"Griffin","year":"2018","journal-title":"Viral Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.3389\/fimmu.2019.02776","article-title":"Editorial: Reverse vaccinology","volume":"10","author":"Moxon","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"120660","DOI":"10.1016\/j.lfs.2022.120660","article-title":"Modern vaccine development via reverse vaccinology to combat antimicrobial resistance","volume":"302","author":"Tobuse","year":"2022","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.immuni.2010.09.017","article-title":"Reverse vaccinology: Developing vaccines in the era of genomics","volume":"33","author":"Sette","year":"2010","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8156","DOI":"10.1016\/j.vaccine.2011.07.142","article-title":"Improving reverse vaccinology with a machine learning approach","volume":"29","author":"Bowman","year":"2011","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105259","DOI":"10.1016\/j.meegid.2022.105259","article-title":"Proteome based mapping and reverse vaccinology techniques to contrive multi-epitope based subunit vaccine (MEBSV) against Streptococcus pyogenes","volume":"100","author":"Aslam","year":"2022","journal-title":"Infect. Genet. Evol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3389\/fimmu.2017.01382","article-title":"Identification of new features from known bacterial protective vaccine antigens enhances rational vaccine design","volume":"8","author":"Ong","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Vivona, S., Bernante, F., and Filippini, F. (2006). NERVE: New enhanced reverse vaccinology environment. BMC Biotechnol., 6.","DOI":"10.1186\/1472-6750-6-35"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1359-6446(03)02689-8","article-title":"Reverse vaccinology","volume":"8","author":"Mora","year":"2003","journal-title":"Drug Discov. Today"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00430-16","DOI":"10.1128\/CVI.00430-16","article-title":"Serum bactericidal antibody responses of adults immunized with the menb-4c vaccine against genetically diverse serogroup B Meningococci","volume":"24","author":"Giuntini","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fimmu.2019.00751","article-title":"The development of a vaccine against meningococcus b using reverse vaccinology","volume":"10","author":"Masignani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mori, M., Stelitano, G., Griego, A., Chiarelli, L.R., Cazzaniga, G., Gelain, A., Pini, E., Camera, M., Canzano, P., and Fumagalli, A. (2022). Synthesis and assessment of the in vitro and ex vivo activity of salicylate synthase (Mbti) inhibitors as new candidates for the treatment of mycobacterial infections. Pharmaceuticals, 15.","DOI":"10.3390\/ph15080992"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"114235","DOI":"10.1016\/j.ejmech.2022.114235","article-title":"Virtual screening and crystallographic studies reveal an unexpected gamma-lactone derivative active against MptpB as a potential antitubercular agent","volume":"234","author":"Cazzaniga","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12026-022-09284-x","article-title":"Reverse vaccinology approach to design a multi-epitope vaccine construct based on the Mycobacterium tuberculosis biomarker PE_PGRS17","volume":"70","author":"Moodley","year":"2022","journal-title":"Immunol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41598-020-80899-6","article-title":"In silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology","volume":"11","author":"Bibi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_30","first-page":"1647","article-title":"Design of multi-epitope based vaccine against Mycobacterium tuberculosis: A subtractive proteomics and reverse vaccinology based immunoinformatics approach","volume":"11","author":"Nayak","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/CMR.00068-09","article-title":"The changing microbial epidemiology in cystic fibrosis","volume":"23","author":"Lipuma","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3389\/fmicb.2017.01592","article-title":"Burkholderia cenocepacia infections in cystic fibrosis patients: Drug resistance and therapeutic approaches","volume":"8","author":"Scoffone","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tim.2019.12.005","article-title":"Vaccines to overcome antibiotic resistance: The challenge of Burkholderia cenocepacia","volume":"28","author":"Scoffone","year":"2020","journal-title":"Trends Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/IAI.01668-06","article-title":"Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia","volume":"75","author":"Bertot","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00430-009-0137-2","article-title":"Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine","volume":"199","author":"Makidon","year":"2010","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1128\/IAI.01248-15","article-title":"Linocin and OmpW are involved in attachment of the cystic fibrosis-associated pathogen Burkholderia cepacia complex to lung epithelial cells and protect mice against infection","volume":"84","author":"McClean","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Pradenas, G.A., Myers, J.N., and Torres, A.G. (2017). Characterization of the Burkholderia cenocepacia TonB mutant as a potential live attenuated vaccine. Vaccines, 5.","DOI":"10.3390\/vaccines5040033"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s40475-015-0042-2","article-title":"Recent advances in Burkholderia mallei and B. pseudomallei research","volume":"2","author":"Hatcher","year":"2015","journal-title":"Curr. Trop. Med. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mott, T.M., Vijayakumar, S., Sbrana, E., Endsley, J.J., and Torres, A.G. (2015). Characterization of the Burkholderia mallei tonB mutant and its potential as a backbone strain for vaccine development. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003863"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nbt.2019.08.006","article-title":"New insights into the immunoproteome of B. cenocepacia J2315 using serum samples from cystic fibrosis patients","volume":"54","author":"Sousa","year":"2020","journal-title":"New Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Shinoy, M., Dennehy, R., Coleman, L., Carberry, S., Schaffer, K., Callaghan, M., Doyle, S., and McClean, S. (2013). Immunoproteomic analysis of proteins expressed by two related pathogens, Burkholderia multivorans and Burkholderia cenocepacia, during human infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080796"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/elps.200900050","article-title":"Membrane proteins and proteomics: Love is possible, but so difficult","volume":"30","author":"Rabilloud","year":"2009","journal-title":"Electrophoresis"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sousa, S.A., Seixas, A.M.M., Mandal, M., Rodriguez-Ortega, M.J., and Leitao, J.H. (2020). Characterization of the Burkholderia cenocepacia J2315 surface-exposed immunoproteome. Vaccines, 8.","DOI":"10.3390\/vaccines8030509"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jprot.2013.03.035","article-title":"Surfomics: Shaving live organisms for a fast proteomic identification of surface proteins","volume":"97","year":"2014","journal-title":"J. Proteom."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Capelli, R., Peri, C., Villa, R., Nithichanon, A., Conchillo-Sole, O., Yero, D., Gagni, P., Chiari, M., Lertmemongkolchai, G., and Cretich, M. (2018). BPSL1626: Reverse and structural vaccinology reveal a novel candidate for vaccine design against Burkholderia pseudomallei. Antibodies, 7.","DOI":"10.3390\/antib7030026"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Irfan, M., Khan, S., Hameed, A.R., Al-Harbi, A.I., Abideen, S.A., Ismail, S., Ullah, A., Abbasi, S.W., and Ahmad, S. (2022). Computational based designing of a multi-epitopes vaccine against Burkholderia mallei. Vaccines, 10.","DOI":"10.3390\/vaccines10101580"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s43141-022-00379-4","article-title":"In silico designing of a multi-epitope vaccine against Burkholderia pseudomallei: Reverse vaccinology and immunoinformatics","volume":"20","author":"Shahab","year":"2022","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"929400","DOI":"10.3389\/fmicb.2022.929400","article-title":"Reverse vaccinology and immunoinformatic assisted designing of a multi-epitopes based vaccine against nosocomial Burkholderia cepacia","volume":"13","author":"Alsowayeh","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of Mycobacterium infections: Compassionate-use of phages in twenty patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e0002821","DOI":"10.1128\/CMR.00028-21","article-title":"Invasive Haemophilus influenzae infections after 3 decades of hib protein conjugate vaccine use","volume":"34","author":"Slack","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18869\/acadpub.ibj.21.2.69","article-title":"Vaccine candidates against nontypeable Haemophilus influenzae: A review","volume":"21","author":"Behrouzi","year":"2017","journal-title":"Iran. Biomed. J."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"D\u2019Mello, A., Ahearn, C.P., Murphy, T.F., and Tettelin, H. (2019). ReVac: A reverse vaccinology computational pipeline for prioritization of prokaryotic protein vaccine candidates. BMC Genomics, 20.","DOI":"10.1186\/s12864-019-6195-y"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0264-410X(00)00288-7","article-title":"Developing a nontypeable Haemophilus influenzae (NTHi) vaccine","volume":"19","author":"Poolman","year":"2000","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1128\/iai.61.5.1950-1957.1993","article-title":"Evaluation of mixtures of purified Haemophilus influenzae outer membrane proteins in protection against challenge with nontypeable H. influenzae in the chinchilla otitis media model","volume":"61","author":"Green","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.thorsurg.2018.09.008","article-title":"Nontuberculous mycobacterial infections in cystic fibrosis","volume":"29","author":"Martiniano","year":"2019","journal-title":"Thorac. Surg. Clin."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Degiacomi, G., Sammartino, J.C., Chiarelli, L.R., Riabova, O., Makarov, V., and Pasca, M.R. (2019). Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235868"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Abdelaal, H.F.M., Chan, E.D., Young, L., Baldwin, S.L., and Coler, R.N. (2022). Mycobacterium abscessus: It\u2019s complex. Microorganisms, 10.","DOI":"10.3390\/microorganisms10071454"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fimmu.2019.00234","article-title":"BCG vaccination induces M. avium and M. abscessus cross-protective immunity","volume":"10","author":"Abate","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.vaccine.2015.03.030","article-title":"Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: The Mycobacterium abscessus model","volume":"33","author":"Rottman","year":"2015","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/IAI.00359-16","article-title":"MgtC as a host-induced factor and vaccine candidate against Mycobacterium abscessus infection","volume":"84","author":"Belon","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fcimb.2020.00432","article-title":"A TLR2-Activating Fraction from Mycobacterium abscessus rough variant demonstrates vaccine and diagnostic potential","volume":"10","author":"Roux","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Dohal, M., Porvaznik, I., Solovic, I., and Mokry, J. (2021). Whole genome sequencing in the management of non-tuberculous mycobacterial infections. Microorganisms, 9.","DOI":"10.3390\/microorganisms9112237"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Cornejo-Granados, F., Kohl, T.A., Sotomayor, F.V., Andres, S., Hernandez-Pando, R., Hurtado-Ramirez, J.M., Utpatel, C., Niemann, S., Maurer, F.P., and Ochoa-Leyva, A. (2021). Secretome characterization of clinical isolates from the Mycobacterium abscessus complex provides insight into antigenic differences. BMC Genomics, 22.","DOI":"10.1186\/s12864-021-07670-7"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11197","DOI":"10.1038\/s41598-021-90868-2","article-title":"Designing a multi-epitope vaccine against Mycobacteroides abscessus by pangenome-reverse vaccinology","volume":"11","author":"Dar","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Hamad, A.S., Edward, E.A., Sheta, E., Aboushleib, H.M., and Bahey-El-Din, M. (2022). Iron acquisition proteins of Pseudomonas aeruginosa as potential vaccine targets: In silico analysis and in vivo evaluation of protective efficacy of the hemophore HasAp. Vaccines, 11.","DOI":"10.3390\/vaccines11010028"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3389\/fimmu.2018.03021","article-title":"Genome-based approach delivers vaccine candidates against Pseudomonas aeruginosa","volume":"9","author":"Bianconi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1007\/s10989-021-10255-3","article-title":"Quest for novel preventive and therapeutic options against multidrug-resistant Pseudomonas aeruginosa","volume":"27","author":"Irum","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1038\/s41598-019-41496-4","article-title":"Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa","volume":"9","author":"Solanki","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Motta, S., Vecchietti, D., Martorana, A.M., Brunetti, P., Bertoni, G., Polissi, A., Mauri, P., and Di Silvestre, D. (2020). The landscape of Pseudomonas aeruginosa membrane-associated proteins. Cells, 9.","DOI":"10.3390\/cells9112421"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbrc.2019.03.092","article-title":"Lectin activity of Pseudomonas aeruginosa vaccine candidates PSE17-1, PSE41-5 and PSE54","volume":"513","author":"Day","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygeno.2017.05.001","article-title":"Prediction of vaccine candidates against Pseudomonas aeruginosa: An integrated genomics and proteomics approach","volume":"109","author":"Rashid","year":"2017","journal-title":"Genomics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"104389","DOI":"10.1016\/j.compbiomed.2021.104389","article-title":"Designing multi-epitope vaccine against Staphylococcus aureus by employing subtractive proteomics, reverse vaccinology and immuno-informatics approaches","volume":"132","author":"Ahmad","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Naorem, R.S., Pangabam, B.D., Bora, S.S., Goswami, G., Barooah, M., Hazarika, D.J., and Fekete, C. (2022). Identification of putative vaccine and drug targets against the methicillin-resistant Staphylococcus aureus by reverse vaccinology and subtractive genomics approaches. Molecules, 27.","DOI":"10.3390\/molecules27072083"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105149","DOI":"10.1016\/j.meegid.2021.105149","article-title":"Investigation of novel putative immunogenic targets against Staphylococcus aureus using a reverse vaccinology strategy","volume":"96","author":"Bolourchi","year":"2021","journal-title":"Infect. Genet. Evol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Holtfreter, S., Kolata, J., Stentzel, S., Bauerfeind, S., Schmidt, F., Sundaramoorthy, N., and Broker, B.M. (2016). Omics approaches for the study of adaptive immunity to Staphylococcus aureus and the selection of vaccine candidates. Proteomes, 4.","DOI":"10.3390\/proteomes4010011"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Rahman, S., Sarkar, K., and Das, A.K. (2023). Exploring staphylococcal superantigens to design a potential multi-epitope vaccine against Staphylococcus aureus: An in-silico reverse vaccinology approach. J. Biomol. Struct. Dyn., 1\u201315.","DOI":"10.1080\/07391102.2023.2171138"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/7\/1221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:09:21Z","timestamp":1760126961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/7\/1221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,9]]},"references-count":76,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["vaccines11071221"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11071221","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,9]]}}}